Get the Stockscreener App
0.97
0.51%
-0.005
After Hours:
.97
Cytomed Therapeutics Ltd stock is traded at $0.97, with a volume of 1,299.
It is down -0.51% in the last 24 hours and down -24.81% over the past month.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
See More
Previous Close:
$0.975
Open:
$0.9501
24h Volume:
1,299
Relative Volume:
0.07
Market Cap:
$11.48M
Revenue:
$248.40K
Net Income/Loss:
$-3.05M
P/E Ratio:
-3.7151
EPS:
-0.2611
Net Cash Flow:
$-3.30M
1W Performance:
-3.00%
1M Performance:
-24.81%
6M Performance:
-30.22%
1Y Performance:
-55.88%
1-Day Range:
$0.9401
$1.015
1-Week Range:
$0.94
$1.08
52-Week Range:
$0.6801
$3.68
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Name
Cytomed Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare GDTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
0.97 | 12.19M | 248.40K | -3.05M | -3.30M | -0.2611 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomed Therapeutics Ltd Stock (GDTC) Latest News
CytoMed, a Singapore Biotech, RevolutionizesCancer Treatment Using Donor Immune Cells - openPR.com
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 6K CytoMed Therapeutics Ltd For: 23 June - Investing.com UK
CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank - TipRanks
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com - Investing.com Nigeria
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytoMed Therapeutics Ltd (GDTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Institutional Confidence - TradingKey
CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytoMed Therapeutics Ltd (GDTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals - Stock Titan
CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into FocusDouble Top - newsline.com
GDTCCytoMed Therapeutics Ltd Stock Price and Quote - Finviz
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares - Stock Titan
CytoMed Therapeutics LtdA Rising Star in Singapore's Cancer Biotechnology Sector - openPR.com
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News - Moomoo
CytoMed Therapeutics Limited is accelerating its international expansion - openPR.com
CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3 - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares - Stock Titan
CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase - Stock Titan
[144] CytoMed Therapeutics Ltd SEC Filing - Stock Titan
GDTC Price Today: CytoMed Therapeutics Limited Stock Price, Quote & Chart | MEXC - MEXC
TradingKey - TradingKey
CytoMed Renames Subsidiary to Drive Asian and International Expansion - TipRanks
CytoMed Therapeutics (GDTC) refocuses on Asia with new subsidiary name - Stock Titan
CytoMed Therapeutics : Audited Financial Statements for FY2025 - marketscreener.com
CytoMed (GDTC) Stock Hedge Funds (Slight Downtick) 2026-04-18PCR Mean Reversion - Newser
CytoMed (GDTC) Stock Deal Activity (Slight Rise) 2026-04-16Combination Correction - newsline.com
CytoMed Therapeutics (GDTC) 2026 AGM to vote on takeover code waiver, new share issuance - Stock Titan
GDTC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GDTC Stock Analysis: CytoMed Therapeutics Limited gains 3 percent at 1.03 mark - Xã Châu Thành
Rising R&D loss as CytoMed (NASDAQ: GDTC) advances γδ T cell therapies - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) flags losses and funding needs in 2025 report - Stock Titan
Stop Loss: Why is CytoMed Therapeutics Limited stock going upWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
AI Stocks: Can CytoMed Therapeutics Limited withstand a market correctionMarket Performance Recap & Scalable Portfolio Growth Ideas - baoquankhu1.vn
GDTC SEC FilingsCytoMed Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
GDTC Technical Analysis & ETF Price Forecast - Intellectia AI
GDTC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GDTC Should I Buy - Intellectia AI
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 1% – Still a Buy? - Defense World
Insider Sell: What analysts say about CytoMed Therapeutics Limited stock2025 Year in Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - Yahoo Finance
Cytomed Therapeutics Ltd Stock (GDTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):